☆ 4.3 Editorial Material

PD-L1/PD-1: new kid on the immune metabolic block

ONCOTARGET (2017)

Journal

ONCOTARGET

Volume 8, Issue 43, Pages 73364-73365

Publisher

IMPACT JOURNALS LLC

DOI: 10.18632/oncotarget.20639

Keywords

immune checkpoints; immune metabolism; PDL1/PD-1

Categories

Oncology Cell Biology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1

Ganji Purnachandra Nagaraju, Rama Rao Malla, Riyaz Basha, Ion G. Motofei

Summary: This review provides up-to-date information on the role of PD-1 and PD-L1 in the development of immune tolerance in pancreatic cancer and discusses current clinical trials and known outcomes. It also explores the involvement of PD-1/PD-L1 signaling in pancreatic cancer stem cells and metastasis. The review reviews the safety, tolerance, and efficacy of clinically important regimens of PD-1/PD-L1 blocking agents and targeted therapeutics.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction

Raphael Le Biannic, Romain Magnez, Frederique Klupsch, Natascha Leleu-Chavain, Bryan Thiroux, Morgane Tardy, Hassiba El Bouazzati, Xavier Dezitter, Nicolas Renault, Gerard Vergoten, Christian Bailly, Bruno Quesnel, Xavier Thuru, Regis Millet

Summary: Immuno-therapy using checkpoint inhibitor monoclonal antibodies against PD-1 and PD-L1 has shown improved survival in cancer patients. Researchers have synthesized a series of synthetic compounds with nanomolar activity against PD-L1 and characterized their properties using various biophysical techniques. Some small molecules demonstrated high affinity for human PD-L1, disrupting the PD-L1:PD-1 interaction effectively.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Oncology

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge

Summary: Despite advances in immune checkpoint inhibitors (ICI), many tumors still exhibit resistance and fail to respond to treatment. The combination of radiation therapy (RT) and ICI has not shown promising results in clinical trials. Therefore, novel approaches are needed to overcome this resistance and improve clinical outcomes.

ONCOIMMUNOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint

Katarzyna Magiera-Mularz, Katarzyna Kuska, Lukasz Skalniak, Przemyslaw Grudnik, Bogdan Musielak, Jacek Plewka, Justyna Kocik, Malgorzata Stec, Kazimierz Weglarczyk, Dominik Sala, Benedykt Wladyka, Maciej Siedlar, Tad A. Holak, Grzegorz Dubin

Summary: The study reports a macrocyclic peptide p101 capable of blocking the PD-L1/PD-1 immune checkpoint, showing that the interaction is primarily guided by hydrophobic forces. Experimental results demonstrate that p101 can effectively inhibit the interaction between PD-L1 and PD-1 in the cellular environment, releasing the immune response of human T cells.

ADVANCED THERAPEUTICS (2021)

Add to Collection

Review Chemistry, Multidisciplinary

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Qian Wu, Li Jiang, Si-cheng Li, Qiao-jun He, Bo Yang, Ji Cao

Summary: PD-1/PD-L1 signaling pathway is a target for anticancer drugs, and the development of small molecule inhibitors provides a new avenue for tumor immunotherapy.

ACTA PHARMACOLOGICA SINICA (2021)

Add to Collection

Article Multidisciplinary Sciences

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Sneha Berry, Nicolas A. Giraldo, Benjamin F. Green, Tricia R. Cottrell, Julie E. Stein, Elizabeth L. Engle, Haiying Xu, Aleksandra Ogurtsova, Charles Roberts, Daphne Wang, Peter Nguyen, Qingfeng Zhu, Sigfredo Soto-Diaz, Jose Loyola, Inbal B. Sander, Pok Fai Wong, Shlomit Jessel, Joshua Doyle, Danielle Signer, Richard Wilton, Jeffrey S. Roskes, Margaret Eminizer, Seyoun Park, Joel C. Sunshine, Elizabeth M. Jaffee, Alexander Baras, Angelo M. De Marzo, Suzanne L. Topalian, Harriet Kluger, Leslie Cope, Evan J. Lipson, Ludmila Danilova, Robert A. Anders, David L. Rimm, Drew M. Pardoll, Alexander S. Szalay, Janis M. Taube

Summary: A comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections was introduced, allowing high-fidelity single-cell analysis. This platform identified key features in pretreatment melanoma specimens that predicted response to anti-PD-1 therapy, and stratified long-term survival after anti-PD-1 blockade. The signature was validated in an independent cohort of melanoma patients from a different institution.

SCIENCE (2021)

Add to Collection

Review Immunology

Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway

Yuki Nakamori, Eun Jeong Park, Motomu Shimaoka

Summary: Sepsis is a disease characterized by a dysregulated host response to infection, with both inflammation and immune suppression occurring, and no specific treatment has been validated. The challenge lies in the complexity and heterogeneity of sepsis, requiring the selection of homogenous sepsis subgroups for testing experimental therapies. Artificial intelligence may help in identifying the most suitable subgroup for specific pathway inhibitors.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments

Cinzia Vetrei, Margherita Passariello, Guendalina Froechlich, Rosa Rapuano Lembo, Nicola Zambrano, Claudia De Lorenzo

Summary: The study focuses on identifying potent and safe combinations of immunomodulatory monoclonal antibodies for cancer immunotherapy, using an in vitro system to predict efficacy and potential side effects early on. The research provides evidence of interactions between immune checkpoints in tumor cells and explores the functions of different immune checkpoints in cancer cells using clinically validated antibodies. Additionally, the study investigates novel combinations of immunomodulatory antibodies with greater anti-cancer activity and lower cardiotoxic effects.

CANCERS (2021)

Add to Collection

Article Immunology

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells

Karla M. Viramontes, Emily N. Neubert, Julia M. DeRogatis, Roberto Tinoco

Summary: PSGL-1 plays multiple regulatory roles in exhausted T cells, limiting their expansion in tumors and persistently infected hosts. It is also necessary for the long-term maintenance and optimal differentiation of exhausted T cells into specific subsets. Additionally, PSGL-1 restrains the reinvigoration potential of exhausted CD4(+) and CD8(+) T cells during ICI therapy. Targeting PSGL-1 may have therapeutic potential alone or in combination with other ICIs to reinvigorate exhausted T cells in patients with chronic infections or cancer.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

Pratibha Pandey, Fahad Khan, Huda A. Qari, Tarun Kumar Upadhyay, Abdulhameed F. Alkhateeb, Mohammad Oves

Summary: Immunotherapy has made significant progress in cancer treatment through blocking immunological checkpoint pathways. Recent studies have shown that combining immune checkpoint inhibitors with other anticancer drugs can improve their effectiveness. Immune checkpoint blockade also aids in inhibiting angiogenesis and enhancing the immune system's efficacy.

PHARMACEUTICALS (2022)

Add to Collection

Article Oncology

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa

Summary: In highly glycolytic tumors, regulatory T (Treg) cells have higher PD-1 expression compared to effector T cells. Under low-glucose conditions, Treg cells actively absorb lactic acid through monocarboxylate transporter 1 (MCT1), promoting the expression of PD-1, while PD-1 expression by effector T cells is dampened. PD-1 blockade invigorates PD-1-expressing Treg cells, resulting in treatment failure.

CANCER CELL (2022)

Add to Collection

Article Chemistry, Medicinal

Traversing through the Dynamic Protein-Protein InteractionLandscape and Conformational Plasticity of PD-1 for Small-MoleculeDiscovery

Lovika Mittal, Rajiv Tonk, Amit Awasthi, Shailendra Asthana

Summary: Monoclonal antibodies blocking the PD-1/PD-L1 interface have shown remarkable success in treating malignancies, but they may also initiate lethal immune-related adverse events. Small molecules may circumvent the mAb limitations; however, none has entered clinical trials targeting PD-1. The understanding of PD-1's sequence-structure-dynamic-function link is crucial for exploring its binding mechanisms and discovering new small-molecule drugs.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Oncology

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos, Helen Gogas

Summary: Although immune checkpoint inhibitors have significantly improved prognosis for melanoma patients, some patients do not benefit from them. Other immune checkpoint molecules beyond PD-1 and CTLA-4 play a major role in immune evasion. This comprehensive overview provides information on the functional characteristics and therapeutic modalities of various immune checkpoint molecules for melanoma treatment.

CANCERS (2023)

Add to Collection

Review Oncology

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Yu Yuan, Abdalla Adam, Chen Zhao, Honglei Chen

Summary: Immune checkpoint blockade targeting PD-1/PD-L1 has shown promising therapeutic efficacy in various tumors, but resistance can hinder its effectiveness. This review examines the role of PD-L1 in therapy resistance, particularly through the PD-1/PD-L1 pathway, and highlights potential combination therapies to overcome this resistance.

CANCERS (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy

Songlin Liu, Haiyang Wang, Xinzhe Shao, Haonan Chen, Shushu Chao, Yanyan Zhang, Zhaoju Gao, Qingqiang Yao, Pingping Zhang

Summary: Cancer immunotherapy, particularly immune checkpoint blockade targeting programmed cell death receptor-1 (PD-1), has shown promise in various tumors. However, low responsiveness and immune-related adverse effects limit its clinical application. Nanomaterial-based delivery systems have been explored to address these limitations by enabling targeted drug delivery and controlled release. This study reviews the application of nanomaterial carriers in delivering PD-1 inhibitors alone or in combination with other immunomodulators, chemotherapeutic drugs, and photothermal reagents, providing valuable references for designing novel PD-1 blockade therapeutic strategies.

JOURNAL OF NANOBIOTECHNOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Tim-3 is dispensable for allergic inflammation and respiratory tolerance in experimental asthma

Carolin Boehne, Ann-Kathrin Behrendt, Almut Meyer-Bahlburg, Martin Boettcher, Sebastian Drube, Thomas Kamradt, Gesine Hansen

Summary: The study demonstrates that Tim-3 is dispensable for the development of allergic inflammation and induction of respiratory tolerance in mice in an OVA-based model.

PLOS ONE (2021)

Add to Collection

Article Oncology

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis

Martin Boettcher, Heiko Bruns, Simon Voelkl, Junyan Lu, Elisavet Chartomatsidou, Nikos Papakonstantinou, Kristin Mentz, Maike Buettner-Herold, Thorsten Zenz, Marco Herling, Wolfgang Huber, Paolo Ghia, Kostas Stamatopoulos, Andreas Mackensen, Dimitrios Mougiakakos

Summary: Chronic lymphocytic leukemia (CLL) cells efficiently evade immunosurveillance through close interaction with stromal niches in the bone marrow and lymph nodes. Enhanced PD-L1 expression on CLL cells following stromal contact contributes to immune escape, controlled by a Notch-c-Myc-EZH2 signaling axis. Elevated PD-L1 levels confer resistance towards activated autologous T-cells, highlighting potential therapeutic targets for improving immune responses in CLL patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Immunology

β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression

Daniel Hofbauer, Dimitrios Mougiakakos, Luca Broggini, Mario Zaiss, Maike Buettner-Herold, Christian Bach, Bernd Spriewald, Frank Neumann, Savita Bisht, Jens Nolting, Robert Zeiser, Shaima'a Hamarsheh, Martin Eberhardt, Julio Vera, Cristina Visentin, Chiara Maria Giulia De Luca, Fabio Moda, Stefan Haskamp, Cindy Flamann, Martin Boettcher, Katrin Bitterer, Simon Voelkl, Andreas Mackensen, Stefano Ricagno, Heiko Bruns

Summary: This study identifies beta-2-microglobulin as a key driver of inflammation in myeloma-associated macrophages, leading to disease progression and bone destruction via NLRP3 inflammasome activation. Inhibition of NLRP3 may offer a potential therapeutic approach in multiple myeloma.

IMMUNITY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Anticancer Aminoferrocene Derivatives Inducing Production of Mitochondrial Reactive Oxygen Species

Hulya Gizem Ozkan, Vanrajsinh Thakor, Hong-Gui Xu, Galyna Bila, Rostyslav Bilyy, Daria Bida, Martin Boettcher, Dimitrios Mougiakakos, Rainer Tietze, Andriy Mokhir

Summary: Elevated levels of reactive oxygen species (ROS) and deficient mitochondria are weak points of cancer cells. Designing highly potent anticancer drugs that target both ROS and mitochondria is a valid therapeutic strategy. However, limiting the drug effects to cancer cells without affecting normal ones remains a challenge. In this study, we developed novel aminoferrocene derivatives that are chemically stable in the presence of ROS, generate mitochondrial ROS in cancer cells but not normal cells, and exhibit anticancer effects in vivo.

CHEMISTRY-A EUROPEAN JOURNAL (2022)

Add to Collection

Article Hematology

Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset

Martin Boettcher, Konstantinos Panagiotidis, Heiko Bruns, Martina Stumpf, Simon Voelkl, Stefanie Geyh, Barbara Dietel, Thomas Schroeder, Andreas Mackensen, Dimitrios Mougiakakos

Summary: BM stroma acts as a protective niche for AML cells, and upregulation of S100A8/A9 after stromal contact increases therapeutic resistance in AML cells.

BLOOD ADVANCES (2022)

Add to Collection

Article Multidisciplinary Sciences

The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome

Silja Richter, Martin Boettcher, Simon Voelkl, Andreas Mackensen, Evelyn Ullrich, Benedikt Jacobs, Dimitrios Mougiakakos

Summary: This study found that reconstituting immune cells undergo metabolic changes after autologous stem cell transplantation, including increased proliferative activity and upregulation of glycolytic and fatty acid oxidation machinery. This metabolic activation is more pronounced in T-cells of advanced differentiation stages, CD56(bright) NK cells, and CD14(++)CD16(+) intermediate monocytes. Furthermore, persistent metabolic activation is associated with poor disease course in lymphoma patients within the first year following transplantation.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Cell Biology

CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints

Martin Boettcher, Romy Boettcher-Loschinski, Sascha Kahlfuss, Michael Aigner, Andreas Giessl, Andreas Mackensen, Ursula Schloetzer-Schrehardt, Thomas Tueting, Heiko Bruns, Dimitrios Mougiakakos

Summary: This study reveals that CLL cell-derived EVs impair the viability, proliferation, activation, and metabolism of T-cells, while promoting T-cell exhaustion and the formation of regulatory T-cell subsets. The presence of immunological checkpoints (ICs) loaded on CLL-EVs may explain the T-cell dysregulations observed in CLL patients.

CELLS (2022)

Add to Collection

Review Microbiology

Pleiotropic effects of antibiotics on T cell metabolism and T cell-mediated immunity

Tobias Franz, Jonas Negele, Philipp Bruno, Martin Boettcher, Marisa Mitchell-Flack, Lea Reemts, Anna Krone, Dimitrios Mougiakakos, Andreas J. Mueller, Andreas E. Zautner, Sascha Kahlfuss

Summary: Energy metabolism plays a critical role in the activation, differentiation, and effector functions of T cells. Antibiotics have been shown to modulate the metabolism of T cells, thereby impacting their immune responses in diseases such as allergies and autoimmune disorders.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Article Rheumatology

Reset of Inflammatory Priming of Joint Tissue and Reduction of the Severity of Arthritis Flares by Bromodomain Inhibition

Jasna Friscic, Christiane Reinwald, Martin Boettcher, Miranda Houtman, Maximilien Euler, Xi Chen, Kellie Walker, Philipp Kirchner, Honglin Zhu, Benjamin Wirth, Daniela Weidner, Rene Krueger, Vladimir Trajkovic, Arif B. B. Ekici, Kerstin Klein, Dimitrios Mougiakakos, Caroline Ospelt, Georg Schett, Markus H. H. Hoffmann

Summary: The induction of synovial fibroblasts plays a crucial role in the onset of arthritis flares, which is primarily mediated by epigenetic reprogramming. A BET inhibitor can target inflammatory tissue priming and reduce the severity of experimental arthritis in mice.

ARTHRITIS & RHEUMATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Lipotoxicity as a Barrier for T Cell-Based Therapies

Romy Boettcher-Loschinski, Judit Rial Saborido, Martin Boettcher, Sascha Kahlfuss, Dimitrios Mougiakakos

Summary: T-cell-based approaches are increasingly important in cancer treatment, and the relationship between immune cell metabolism and immunotherapy success is crucial. Excessive exposure of T cells to fatty acids, known as lipotoxicity, can have detrimental effects in the context of an altered lipid tumor microenvironment. Understanding T cell-related lipotoxicity and developing potential therapeutic approaches is of great importance.

BIOMOLECULES (2022)

Add to Collection

Article Oncology

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

Giorgia Massacci, Veronica Venafra, Sara Latini, Valeria Bica, Giusj Monia Pugliese, Simone Graziosi, Felix Klingelhuber, Natalie Krahmer, Thomas Fischer, Dimitrios Mougiakakos, Martin Boettcher, Livia Perfetto, Francesca Sacco

Summary: The insertion site of ITDs in the FLT3 gene influences the sensitivity to TKIs therapy in AML. The study identifies the WEE1-CDK1 axis as a conserved role in TKIs resistance and shows that inhibition of WEE1 kinase enhances the pro-apoptotic effect of TKIs therapy. Therefore, combination therapy with WEE1 inhibitor and TKI may improve the clinical outcome of AML patients.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

F. Karl, C. Liang, R. Boettcher-Loschinski, A. Stoll, C. Flamann, S. Richter, C. Lischer, S. Voelkl, B. Jacobs, M. Boettcher, R. Jitschin, H. Bruns, T. Fischer, E. Holler, W. Roesler, T. Dandekar, A. Mackensen, D. Mougiakakos

Summary: Allo-SCT is a curative treatment for hematologic malignancies, relying on the graft-versus-leukemia (GVL) effect of donor T cells. Oxidative stress caused by DNA damage weakens the function of T cells and hampers the GVL effect. High levels of 8-hydroxydeoxyguanosine (8-OHdG), a biomarker for oxidative stress, were associated with enhanced T-cell activation, premature exhaustion, increased relapse risk, and shorter overall survival. Enhancing DNA repair in reconstituting T cells could improve GVL efficacy.

BLOOD (2023)

Add to Collection

Letter Oncology

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach

Giusj Monia Pugliese, Veronica Venafra, Valeria Bica, Giorgia Massacci, Sara Latini, Simone Graziosi, Thomas Fischer, Dimitrios Mougiakakos, Martin Boettcher, Livia Perfetto, Francesca Sacco

LEUKEMIA (2023)

Add to Collection

Article Oncology

Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy

Rebecca Baur, Franziska Karl, Romy Boettcher-Loschinski, Andrej Stoll, Simon Voelkl, Andreas Giessl, Cindy Flamann, Heiko Bruns, Ursula Schloetzer-Schrehardt, Martin Boettcher, Denis M. Schewe, Thomas Fischer, Regina Jitschin, Andreas Mackensen, Dimitrios Mougiakakos

Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for certain hematological malignancies. However, allo-HSCT can also lead to graft-versus-host disease (GvHD) and disease relapse. Recent studies have found that extracellular vesicles (EVs) expressing PD-L1 can suppress T-cell responses and contribute to GvHD and disease relapse in allo-HSCT patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Letter Hematology

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model

Peter Muller, Conny K. Baldauf, Tobias R. Haage, Emmanouil Charakopoulos, Martin Bottcher, Vikas Bhuria, Dimitrios Mougiakakos, Burkhart Schraven, Thomas Fischer

HEMASPHERE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.